CBAY — CymaBay Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $3.73bn
- $3.44bn
- $31.07m
Annual income statement for CymaBay Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 31.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 108 | 52.6 | 87.6 | 93.1 | 133 |
| Operating Profit | -108 | -52.6 | -87.6 | -93.1 | -102 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -103 | -51 | -90 | -106 | -105 |
| Net Income After Taxes | -103 | -51 | -90 | -106 | -105 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -103 | -51 | -90 | -106 | -105 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -103 | -51 | -90 | -106 | -105 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.46 | -0.75 | -1.27 | -1.21 | -0.992 |